Strategic Shift Towards Alzheimer's Lead Program

Exploring the pivotal decision to focus on Alzheimer's as a lead program due to financial constraints and the successful transaction with BMS. The chapter illustrates the CEO's validation, venture capitalists' support, and the unique challenges of drug development for rare diseases.